Viking Therapeutics Inc (NASDAQ:VKTX) traded down 6.3% during trading on Friday . The stock traded as low as $5.01 and last traded at $4.73. 1,674,349 shares traded hands during mid-day trading, an increase of 13% from the average session volume of 1,475,680 shares. The stock had previously closed at $5.05.
Several equities research analysts have recently commented on the company. BidaskClub lowered Viking Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, March 16th. Roth Capital set a $8.00 price objective on Viking Therapeutics and gave the stock a “buy” rating in a research note on Thursday, March 8th. Maxim Group restated a “buy” rating and issued a $8.00 price objective on shares of Viking Therapeutics in a research note on Thursday, March 8th. Finally, ValuEngine lowered Viking Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and an average target price of $7.67.
The stock has a market capitalization of $271.29, a P/E ratio of -6.31 and a beta of 1.81.
A number of hedge funds have recently modified their holdings of the business. Citadel Advisors LLC purchased a new stake in Viking Therapeutics in the 3rd quarter worth $108,000. Creative Planning increased its stake in Viking Therapeutics by 600.0% in the 4th quarter. Creative Planning now owns 70,000 shares of the biotechnology company’s stock worth $284,000 after buying an additional 60,000 shares in the last quarter. Geode Capital Management LLC increased its stake in Viking Therapeutics by 276.2% in the 4th quarter. Geode Capital Management LLC now owns 117,619 shares of the biotechnology company’s stock worth $477,000 after buying an additional 86,355 shares in the last quarter. Cornerstone Capital Inc. purchased a new stake in Viking Therapeutics in the 4th quarter worth $352,000. Finally, Victory Capital Management Inc. purchased a new stake in Viking Therapeutics in the 4th quarter worth $791,000. Institutional investors and hedge funds own 18.36% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Viking Therapeutics (VKTX) Shares Down 6.3%” was reported by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international copyright laws. The correct version of this piece can be accessed at https://stocknewstimes.com/2018/03/23/viking-therapeutics-vktx-shares-down-6-3.html.
About Viking Therapeutics
Viking Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapies for metabolic and endocrine disorders. The Company’s clinical program, VK5211, is an orally available drug candidate, which is in Phase II clinical trial for acute rehabilitation following non-elective hip fracture surgery.
Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.